Complement in therapy and disease Regulating the complement system with antibody-based therapeutics

被引：108
作者：
Melis, Joost P. M. [1 ]
Strumane, Kristin [1 ]
Ruuls, Sigrid R. [1 ]
Beurskens, Frank J. [1 ]
Schuurman, Janine [1 ]
Parren, Paul W. H. I. [1 ,2 ]
机构：
[1] Genmab, NL-3584 CM Utrecht, Netherlands
[2] Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, Leiden, Netherlands
来源：
MOLECULAR IMMUNOLOGY | 2015年 / 67卷 / 02期
关键词：
Complement; Immunology; Antibody; Therapy; Antibody engineering; Cancer; ANTI-CD20; MONOCLONAL-ANTIBODY; LYMPHOCYTIC-LEUKEMIA CELLS; HEMOLYTIC-UREMIC SYNDROME; FACTOR-H POLYMORPHISM; IGG FC-RECEPTOR; DEPENDENT CYTOTOXICITY; EFFECTOR FUNCTIONS; STAPHYLOCOCCUS-AUREUS; SEGMENTAL FLEXIBILITY; MEDIATED LYSIS;
D O I：
10.1016/j.molimm.2015.01.028
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Complement is recognized as a key player in a wide range of normal as well as disease-related immune, developmental and homeostatic processes. Knowledge of complement components, structures, interactions, and cross-talk with other biological systems continues to grow and this leads to novel treatments for cancer, infectious, autoimmune- or age-related diseases as well as for preventing transplantation rejection. Antibodies are superbly suited to be developed into therapeutics with appropriate complement stimulatory or inhibitory activity. Here we review the design, development and future of antibody-based drugs that enhance or dampen the complement system. (C) 2015 The Authors. Published by Elsevier Ltd.
引用
收藏
页码：117 / 130
页数：14
相关论文
共 206 条
[11]   Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer [J].
Baselga, Jose ;
Cortes, Javier ;
Kim, Sung-Bae ;
Im, Seock-Ah ;
Hegg, Roberto ;
Im, Young-Hyuck ;
Roman, Laslo ;
Pedrini, Jose Luiz ;
Pienkowski, Tadeusz ;
Knott, Adam ;
Clark, Emma ;
Benyunes, Mark C. ;
Ross, Graham ;
Swain, Sandra M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (02) :109-119
[12]   Multilocus analysis of age-related macular degeneration [J].
Bergeron-Sawitzke, Julie ;
Gold, Bert ;
Olsh, Adam ;
Schlotterbeck, Sarah ;
Lemon, Kendal ;
Visvanathan, Kala ;
Allikmets, Rando ;
Dean, Michael .
EUROPEAN JOURNAL OF HUMAN GENETICS, 2009, 17 (09) :1190-1199
[13]   PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA (PNH) IS CAUSED BY SOMATIC MUTATIONS IN THE PIG-A GENE [J].
BESSLER, M ;
MASON, PJ ;
HILLMEN, P ;
MIYATA, T ;
YAMADA, N ;
TAKEDA, J ;
LUZZATTO, L ;
KINOSHITA, T .
EMBO JOURNAL, 1994, 13 (01) :110-117
[14]   Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis [J].
Beum, Paul V. ;
Lindorfer, Margaret A. ;
Beurskens, Frank ;
Stukenberg, P. Todd ;
Lokhorst, Henk M. ;
Pawluczkowycz, Andrew W. ;
Parren, Paul W. H. I. ;
van de Winkel, Jan G. J. ;
Taylor, Ronald P. .
JOURNAL OF IMMUNOLOGY, 2008, 181 (01) :822-832
[15]   Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients [J].
Beurskens, Frank J. ;
Lindorfer, Margaret A. ;
Farooqui, Mohammed ;
Beum, Paul V. ;
Engelberts, Patrick ;
Mackus, Wendy J. M. ;
Parren, Paul W. H. I. ;
Wiestner, Adrian ;
Taylor, Ronald P. .
JOURNAL OF IMMUNOLOGY, 2012, 188 (07) :3532-3541
[16]   HUMAN MONOCLONAL IGG ISOTYPES DIFFER IN COMPLEMENT ACTIVATING FUNCTION AT THE LEVEL OF C-4 AS WELL AS CLQ [J].
BINDON, CI ;
HALE, G ;
BRUGGEMANN, M ;
WALDMANN, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1988, 168 (01) :127-142
[17]   First FDA Approval of Dual Anti-HER2 Regimen: Pertuzumab in Combination with Trastuzumab and Docetaxel for HER2-Positive Metastatic Breast Cancer [J].
Blumenthal, Gideon M. ;
Scher, Nancy S. ;
Cortazar, Patricia ;
Chattopadhyay, Somesh ;
Tang, Shenghui ;
Song, Pengfei ;
Liu, Qi ;
Ringgold, Kimberly ;
Pilaro, Anne M. ;
Tilley, Amy ;
King, Kathryn E. ;
Graham, Laurie ;
Rellahan, Barbara L. ;
Weinberg, Wendy C. ;
Chi, Bo ;
Thomas, Colleen ;
Hughes, Patricia ;
Ibrahim, Amna ;
Justice, Robert ;
Pazdur, Richard .
CLINICAL CANCER RESEARCH, 2013, 19 (18) :4911-4916
[18]   Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy [J].
Bologna, Luca ;
Gotti, Elisa ;
Da Roit, Fabio ;
Intermesoli, Tamara ;
Rambaldi, Alessandro ;
Introna, Martino ;
Golay, Josee .
JOURNAL OF IMMUNOLOGY, 2013, 190 (01) :231-239
[19]   Role of complement in neurodegeneration and neuroinflammation [J].
Bonifati, Domenico Marco ;
Kishore, Uday .
MOLECULAR IMMUNOLOGY, 2007, 44 (05) :999-1010
[20]   Relationship between the complement system, risk factors and prediction models in age-related macular degeneration [J].
Bora, Nalini S. ;
Matta, Bharati ;
Lyzogubov, Valeriy V. ;
Bora, Puran S. .
MOLECULAR IMMUNOLOGY, 2015, 63 (02) :176-183
12345678910